88 related articles for article (PubMed ID: 29086375)
1. Combination of Anti-miRNAs Oligonucleotides with Low Amounts of Chemotherapeutic Agents for Pancreatic Cancer Therapy.
Passadouro M; Faneca H
Methods Mol Biol; 2018; 1699():135-154. PubMed ID: 29086375
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer.
Passadouro M; Pedroso de Lima MC; Faneca H
Int J Nanomedicine; 2014; 9():3203-17. PubMed ID: 25061297
[TBL] [Abstract][Full Text] [Related]
3. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic ductal adenocarcinoma: metastatic disease.
Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
[TBL] [Abstract][Full Text] [Related]
5. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
[No Abstract] [Full Text] [Related]
6. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.
Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E
Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A
Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232
[TBL] [Abstract][Full Text] [Related]
8. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
9. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
10. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
[TBL] [Abstract][Full Text] [Related]
11. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.
Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É
Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299
[TBL] [Abstract][Full Text] [Related]
13. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
[TBL] [Abstract][Full Text] [Related]
14. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
15. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
16. New Advances in the Treatment of Metastatic Pancreatic Cancer.
Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
[TBL] [Abstract][Full Text] [Related]
17. Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma.
Li H; Wang P; Deng Y; Zeng M; Tang Y; Zhu WH; Cheng Y
Biomaterials; 2017 Sep; 139():30-38. PubMed ID: 28582716
[TBL] [Abstract][Full Text] [Related]
18. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
19. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T
Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo.
Ye J; Yuen SM; Murphy G; Xie R; Kwok HF
Eur J Pharm Sci; 2017 Dec; 110():62-69. PubMed ID: 28554668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]